Bliss GVS Pharma Limited (BLISSGVS.BO)
INR 120.15
(3.0%)
INR 120.15
(3.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 754.54 Million INR | 6.49% |
| 2022 | 708.58 Million INR | 371.13% |
| 2021 | 150.4 Million INR | -78.04% |
| 2020 | 684.9 Million INR | -29.58% |
| 2019 | 972.65 Million INR | -21.38% |
| 2018 | 1.23 Billion INR | 110.46% |
| 2017 | 587.85 Million INR | -28.35% |
| 2016 | 820.47 Million INR | -0.53% |
| 2015 | 824.82 Million INR | 37.68% |
| 2014 | 599.09 Million INR | 46.15% |
| 2013 | 409.91 Million INR | -28.98% |
| 2012 | 577.2 Million INR | 9.87% |
| 2011 | 525.35 Million INR | 29.3% |
| 2010 | 406.3 Million INR | -2.62% |
| 2009 | 417.21 Million INR | 11.4% |
| 2008 | 374.51 Million INR | 11.01% |
| 2007 | 337.35 Million INR | 778.32% |
| 2006 | 38.4 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 206.97 Million INR | 326.26% |
| 2024 Q2 | 242.6 Million INR | 17.21% |
| 2023 Q2 | 423.06 Million INR | 188.09% |
| 2023 Q1 | 146.85 Million INR | 339.17% |
| 2023 Q4 | -91.47 Million INR | -133.13% |
| 2023 Q3 | 276.1 Million INR | -34.74% |
| 2023 FY | 754.54 Million INR | 6.49% |
| 2022 Q2 | 138.53 Million INR | -46.13% |
| 2022 Q4 | 33.43 Million INR | -88.03% |
| 2022 Q3 | 279.41 Million INR | 101.69% |
| 2022 Q1 | 257.19 Million INR | 31.01% |
| 2022 FY | 708.58 Million INR | 371.13% |
| 2021 FY | 150.4 Million INR | -78.04% |
| 2021 Q2 | 212.66 Million INR | -12.32% |
| 2021 Q1 | 242.54 Million INR | 288.56% |
| 2021 Q4 | 196.32 Million INR | 139.18% |
| 2021 Q3 | -501.12 Million INR | -335.64% |
| 2020 Q3 | 255.5 Million INR | 57.8% |
| 2020 Q2 | 161.92 Million INR | 0.0% |
| 2020 Q4 | 62.42 Million INR | -75.57% |
| 2020 Q1 | 161.92 Million INR | 85.11% |
| 2020 FY | 684.9 Million INR | -29.58% |
| 2019 Q1 | 337.9 Million INR | 86.61% |
| 2019 Q2 | 309.81 Million INR | -8.31% |
| 2019 Q3 | 237.45 Million INR | -23.35% |
| 2019 Q4 | 87.47 Million INR | -63.16% |
| 2019 FY | 972.65 Million INR | -21.38% |
| 2018 Q2 | 414.56 Million INR | 128.94% |
| 2018 Q1 | 181.07 Million INR | 226.49% |
| 2018 FY | 1.23 Billion INR | 110.46% |
| 2018 Q4 | 181.07 Million INR | -29.91% |
| 2018 Q3 | 258.36 Million INR | -37.68% |
| 2017 Q1 | 211.92 Million INR | -36.02% |
| 2017 FY | 587.85 Million INR | -28.35% |
| 2017 Q4 | -143.15 Million INR | -179.88% |
| 2017 Q3 | 179.2 Million INR | -47.27% |
| 2017 Q2 | 339.87 Million INR | 60.38% |
| 2016 Q4 | 331.23 Million INR | 146.62% |
| 2016 Q3 | 134.31 Million INR | -8.38% |
| 2016 Q2 | 146.6 Million INR | -29.63% |
| 2016 Q1 | 208.32 Million INR | 17.81% |
| 2016 FY | 820.47 Million INR | -0.53% |
| 2015 Q3 | 222.14 Million INR | -3.59% |
| 2015 Q1 | 195.42 Million INR | 0.0% |
| 2015 Q4 | 176.83 Million INR | -20.4% |
| 2015 FY | 824.82 Million INR | 37.68% |
| 2015 Q2 | 230.42 Million INR | 17.91% |
| 2014 FY | 599.09 Million INR | 46.15% |
| 2013 FY | 409.91 Million INR | -28.98% |
| 2012 Q2 | 246.93 Million INR | 46.16% |
| 2012 Q4 | 67.42 Million INR | -28.19% |
| 2012 FY | 577.2 Million INR | 9.87% |
| 2012 Q1 | 168.94 Million INR | 0.0% |
| 2012 Q3 | 93.88 Million INR | -61.98% |
| 2011 FY | 525.35 Million INR | 29.3% |
| 2010 FY | 406.3 Million INR | -2.62% |
| 2009 FY | 417.21 Million INR | 11.4% |
| 2008 FY | 374.51 Million INR | 11.01% |
| 2007 FY | 337.35 Million INR | 778.32% |
| 2006 FY | 38.4 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 87.747% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 97.622% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 83.976% |
| Granules India Limited | 4.05 Billion INR | 81.384% |
| Indoco Remedies Limited | 984.6 Million INR | 23.366% |
| Achyut Healthcare Limited | 5.73 Million INR | -13063.66% |
| Ajanta Pharma Limited | 8.16 Billion INR | 90.755% |
| Alkem Laboratories Limited | 17.95 Billion INR | 95.798% |
| Alpa Laboratories Limited | 167.76 Million INR | -349.761% |
| Brooks Laboratories Limited | -195.91 Million INR | 485.129% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | 53.282% |
| Bajaj HealthCare Limited | -837.93 Million INR | 190.048% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 98.645% |
| Eris Lifesciences Limited | 3.91 Billion INR | 80.751% |
| FDC Limited | 3.05 Billion INR | 75.279% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 105.025% |
| Gufic Biosciences Limited | 861.35 Million INR | 12.401% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 82.076% |
| Ipca Laboratories Limited | 5.47 Billion INR | 86.215% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | -235.904% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | 482.464% |
| Lasa Supergenerics Limited | -217.3 Million INR | 447.225% |
| Laurus Labs Limited | 1.6 Billion INR | 53.003% |
| Lupin Limited | 19.14 Billion INR | 96.059% |
| Mankind Pharma Limited | 19.12 Billion INR | 96.056% |
| Medicamen Biotech Limited | 109.31 Million INR | -590.276% |
| Medico Remedies Limited | 82.9 Million INR | -810.083% |
| Megasoft Limited | -127.46 Million INR | 691.955% |
| NATCO Pharma Limited | 13.88 Billion INR | 94.565% |
| Piramal Pharma Limited | 178.2 Million INR | -323.424% |
| RPG Life Sciences Limited | 876.6 Million INR | 13.924% |
| Sigachi Industries Limited | 571.8 Million INR | -31.958% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 99.212% |
| Suven Pharmaceuticals Limited | 3 Billion INR | 74.872% |
| Syncom Formulations (India) Limited | 253.14 Million INR | -198.07% |
| Unichem Laboratories Limited | -704.74 Million INR | 207.066% |
| Wanbury Limited | 559.56 Million INR | -34.845% |
| Windlas Biotech Limited | 581.87 Million INR | -29.675% |
| ZIM Laboratories Limited | 172.46 Million INR | -337.506% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 98.045% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 119.486% |
| Divi's Laboratories Limited | 16 Billion INR | 95.284% |
| Hester Biosciences Limited | 188.89 Million INR | -299.461% |
| Procter & Gamble Health Limited | 2 Billion INR | 62.457% |
| Amrutanjan Health Care Limited | 449.72 Million INR | -67.778% |
| Bal Pharma Limited | 73.92 Million INR | -920.726% |
| Strides Pharma Science Limited | -706.14 Million INR | 206.854% |
| Venus Remedies Limited | 284.9 Million INR | -164.837% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | 65.213% |
| Nectar Lifesciences Limited | 49.95 Million INR | -1410.593% |
| Shilpa Medicare Limited | 318.74 Million INR | -136.725% |
| Aarti Drugs Limited | 1.71 Billion INR | 55.982% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | 43.871% |
| Suven Life Sciences Limited | -1.05 Billion INR | 171.809% |
| Ind-Swift Limited | 142.31 Million INR | -430.198% |
| Valiant Laboratories Limited | 3.19 Million INR | -23508.917% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 86.346% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 113.298% |
| Themis Medicare Limited | 435.23 Million INR | -73.363% |
| Hikal Limited | 696.02 Million INR | -8.408% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 95.445% |
| Sequent Scientific Limited | -358.69 Million INR | 310.36% |
| Novartis India Limited | 851.9 Million INR | 11.428% |
| Wockhardt Limited | -4.63 Billion INR | 116.297% |
| Jubilant Pharmova Limited | 771 Million INR | 2.135% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | -10539.326% |
| Neuland Laboratories Limited | 3 Billion INR | 74.855% |
| Morepen Laboratories Limited | 961.59 Million INR | 21.533% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | -416.759% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | 931.753% |